Lucid Diagnostics Inc (NASDAQ: LUCD) on Tuesday, plunged -5.04% from the previous trading day, before settling in for the closing price of $1.19. Within the past 52 weeks, LUCD’s price has moved between $0.63 and $1.80.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 119.69%. The company achieved an average annual earnings per share of 29.75%. With a float of $32.98 million, this company’s outstanding shares have now reached $63.07 million.
Let’s determine the extent of company efficiency that accounts for 72 employees. In terms of profitability, gross margin is -80.14%, operating margin of -1059.66%, and the pretax margin is -1047.61%.
Lucid Diagnostics Inc (LUCD) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Lucid Diagnostics Inc is 62.03%, while institutional ownership is 5.20%.
Lucid Diagnostics Inc (LUCD) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.75% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 40.08% during the next five years compared to -54.43% drop over the previous five years of trading.
Lucid Diagnostics Inc (NASDAQ: LUCD) Trading Performance Indicators
Lucid Diagnostics Inc (LUCD) is currently performing well based on its current performance indicators. A quick ratio of 1.03 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Lucid Diagnostics Inc (LUCD)
Looking closely at Lucid Diagnostics Inc (NASDAQ: LUCD), its last 5-days average volume was 2.71 million, which is a jump from its year-to-date volume of 0.84 million. As of the previous 9 days, the stock’s Stochastic %D was 10.33%. Additionally, its Average True Range was 0.15.
During the past 100 days, Lucid Diagnostics Inc’s (LUCD) raw stochastic average was set at 36.18%, which indicates a significant increase from 5.63% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.78% in the past 14 days, which was higher than the 84.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3857, while its 200-day Moving Average is $0.9854. However, in the short run, Lucid Diagnostics Inc’s stock first resistance to watch stands at $1.1850. Second resistance stands at $1.2400. The third major resistance level sits at $1.2750. If the price goes on to break the first support level at $1.0950, it is likely to go to the next support level at $1.0600. Should the price break the second support level, the third support level stands at $1.0050.
Lucid Diagnostics Inc (NASDAQ: LUCD) Key Stats
Market capitalization of the company is 116.91 million based on 90,754K outstanding shares. Right now, sales total 4,350 K and income totals -45,530 K. The company made 1,200 K in profit during its latest quarter, and -11,540 K in sales during its previous quarter.
